Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized placebo-controlled dose-ranging study of intravenous MIJ821 added to standard antidepressant care in hospitalized adults with major depressive disorder and suicidal ideation with intent
NL-OMON51020Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of onfasprodil in major depressive disorder (MDD) (7 arms), sponsored by Novartis. Primary endpoint: Change from baseline in MADRS total score at 24 hours after start of first infusion. Started Jan 2022; status: active, not recruiting.
02
Drugs
onfasprodil
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON51020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51020.